Abstract：
OBJECTIVE: Microwave ablation (MWA) has achieved excellent long-term efficacy in treating unifocal papillary thyroid microcarcinoma (UPTMC). The therapeutic effect of this treatment on multifocal papillary thyroid microcarcinoma (MPTMC) is unknown. Therefore, we evaluated the long-term efficacy of MWA for low-risk MPTMC and to provide evidence-based medicine for the revision of clinical guidelines.
METHODS: This study included 66 MPTMC patients with a total of 158 lesions, all of whom received MWA. We collected and retrospectively analyzed the patients\' follow-up data before MWA, at 1, 3, 6, and 12 months posttreatment and every 6 months thereafter until 5 years posttreatment. We evaluated the MWA complication rate, technical success rate (TSR), lesion volume reduction rate (VRR), and complete disappearance rate (CDR) during follow-up and in those patients with tumor progression and delayed surgery.
RESULTS: After 60 months of follow-up, all 158 lesions disappeared in 66 patients, and the volume was reduced from 43.82 mm3 to 0.00 mm3. The TSR and VRR were both 100%. The CDRs at 1 year, 2 years, and 3 years were 57.59%, 93.67%, and 100%, respectively. The complication rate was 3.03% (2/66), and the incidence of tumor progression was 3.03% (2/66), including one new intrathyroidal lesion and one cervical lymph node metastasis (LNM). These lesions were retreated with MWA, and the lesions disappeared during the follow-up period.
CONCLUSIONS: Ultrasound-guided MWA for low-risk MPTMC is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance (AS).
CONCLUSIONS: This study concludes that ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance.
CONCLUSIONS: • Ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective. • During 5 years of follow-up, multifocal papillary thyroid microcarcinoma patients treated with microwave ablation had a favorable prognosis. • To provide evidence-based medicine for the revision of clinical guidelines.
METHODS: This study included 66 MPTMC patients with a total of 158 lesions, all of whom received MWA. We collected and retrospectively analyzed the patients\' follow-up data before MWA, at 1, 3, 6, and 12 months posttreatment and every 6 months thereafter until 5 years posttreatment. We evaluated the MWA complication rate, technical success rate (TSR), lesion volume reduction rate (VRR), and complete disappearance rate (CDR) during follow-up and in those patients with tumor progression and delayed surgery.
RESULTS: After 60 months of follow-up, all 158 lesions disappeared in 66 patients, and the volume was reduced from 43.82 mm3 to 0.00 mm3. The TSR and VRR were both 100%. The CDRs at 1 year, 2 years, and 3 years were 57.59%, 93.67%, and 100%, respectively. The complication rate was 3.03% (2/66), and the incidence of tumor progression was 3.03% (2/66), including one new intrathyroidal lesion and one cervical lymph node metastasis (LNM). These lesions were retreated with MWA, and the lesions disappeared during the follow-up period.
CONCLUSIONS: Ultrasound-guided MWA for low-risk MPTMC is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance (AS).
CONCLUSIONS: This study concludes that ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective and may serve as an alternative option for patients who refuse surgery or active surveillance.
CONCLUSIONS: • Ultrasound-guided microwave ablation for low-risk multifocal papillary thyroid microcarcinoma is safe and effective. • During 5 years of follow-up, multifocal papillary thyroid microcarcinoma patients treated with microwave ablation had a favorable prognosis. • To provide evidence-based medicine for the revision of clinical guidelines.
摘要：
目的：微波消融（MWA）治疗单灶甲状腺乳头状微小癌（UPTMC）具有良好的远期疗效。这种治疗对多灶性甲状腺乳头状微小癌（MPTMC）的治疗效果尚不清楚。因此,我们评估了MWA治疗低危MPTMC的长期疗效,并为临床指南的修订提供循证医学依据.
方法：本研究纳入66例MPTMC患者，共158个病灶，所有人都收到了MWA。我们收集并回顾性分析了MWA之前的患者随访数据，在治疗后1,3,6和12个月以及之后每6个月直到治疗后5年.我们评估了MWA并发症发生率，技术成功率(TSR)病变体积减少率（VRR），随访期间以及肿瘤进展和手术延迟的患者的完全消失率（CDR）。
结果：经过60个月的随访，66例患者的158个病灶全部消失,体积从43.82mm3减少到0.00mm3。TSR和VRR均为100%。1年的CDR，2年,3年占57.59%，93.67%,100%,分别。并发症发生率为3.03%(2/66),肿瘤进展的发生率为3.03%(2/66),包括一个新的甲状腺内病变和一个颈淋巴结转移（LNM）。这些病变用MWA治疗,随访期间病灶消失。
结论：超声引导下的MWA治疗低危MPTMC是安全有效的，可以作为拒绝手术或主动监测（AS）的患者的替代选择。
结论：本研究得出结论，超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效，可作为拒绝手术或主动监测的患者的替代选择。
结论：•超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效。•在5年的随访期间，多灶性甲状腺微小乳头状癌患者接受微波消融治疗预后良好.•为临床指南的修订提供循证医学。
方法：本研究纳入66例MPTMC患者，共158个病灶，所有人都收到了MWA。我们收集并回顾性分析了MWA之前的患者随访数据，在治疗后1,3,6和12个月以及之后每6个月直到治疗后5年.我们评估了MWA并发症发生率，技术成功率(TSR)病变体积减少率（VRR），随访期间以及肿瘤进展和手术延迟的患者的完全消失率（CDR）。
结果：经过60个月的随访，66例患者的158个病灶全部消失,体积从43.82mm3减少到0.00mm3。TSR和VRR均为100%。1年的CDR，2年,3年占57.59%，93.67%,100%,分别。并发症发生率为3.03%(2/66),肿瘤进展的发生率为3.03%(2/66),包括一个新的甲状腺内病变和一个颈淋巴结转移（LNM）。这些病变用MWA治疗,随访期间病灶消失。
结论：超声引导下的MWA治疗低危MPTMC是安全有效的，可以作为拒绝手术或主动监测（AS）的患者的替代选择。
结论：本研究得出结论，超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效，可作为拒绝手术或主动监测的患者的替代选择。
结论：•超声引导下微波消融治疗低危多灶性甲状腺微小乳头状癌安全有效。•在5年的随访期间，多灶性甲状腺微小乳头状癌患者接受微波消融治疗预后良好.•为临床指南的修订提供循证医学。
